160 trends tracked about this subject — the full history, oldest to newest below.
New research indicates that GLP-1 medications like Ozempic and Wegovy may significantly reduce the frequency of asthma attacks and COPD flare-ups.
A new observational study links weight regain following the use of obesity medications to an increased risk of suicidal thoughts.
Prescriptions for GLP-1 medications among children in the United States have surged by over 30,000% since 2019.
Recent coverage highlights a potential new therapeutic benefit for GLP-1 weight-loss drugs regarding sleep apnea.
Novo Nordisk faces a strategic divide as its childhood obesity drug succeeds in trials while its heart drug program suffers multiple terminations.
New research published in Nature investigates whether GLP-1 receptor agonists can slow the biological process of ageing based on a study involving mice.
New research indicates that semaglutide treatment administered late in life can slow the aging process and extend the lifespan of female mice.
Patients using GLP-1 medications for life-changing health improvements are now questioning if these treatments require lifelong commitment.
Recent studies reveal a surge in US children under 12 being prescribed weight-loss drugs like GLP-1.
A new scientific study has identified a genetic link between the use of GLP-1 weight-loss medications and increased hair loss in men.
New reports suggest popular GLP‑1 weight‑loss drugs may trigger male pattern baldness, sparking medical and public‑interest scrutiny.
Recent reporting examines the widespread prescribing of GLP-1 medications and their broad societal and biological impacts.
Diabetic GLP-1 medications are linked to an increased risk of hair loss among men, according to Penn Medicine coverage.
Recent studies indicate that GLP-1 weight loss medications may worsen or accelerate hair loss in men.
A growing cultural and medical debate is emerging over the use of GLP-1 medications, focusing on the tension between clinical benefits and social stigma.
Recent reporting examines the safety, maintenance, and potential dangers of microdosing GLP-1 weight-loss medications.
Recent studies reveal that the GLP-1 receptor agonist semaglutide extends lifespan and slows physiological aging in animal models.
7 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
6 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Experts call for safer weight loss methods as public and medical attention intensifies around the use and effectiveness of GLP-1 medications.
7 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Corporate insurance coverage for GLP-1 weight-loss drugs is declining as companies like PepsiCo remove these benefits to manage pharmacy costs.
Emerging research and patient reports suggest GLP-1 medications may have an unexpected application in treating addiction and alcohol use disorder.
1 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Ozempic, a popular weight‑loss drug, is now being linked to benefits for serious mental illnesses such as bipolar disorder.
7 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
9 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
1 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Medical experts and researchers are analyzing whether the rise of GLP-1 drugs signals a turning point for obesity rates in the United States.
Eli Lilly has introduced Foundayo, a new daily oral weight-loss medication, to the United Kingdom market, driving a significant rise in company stock.
Emerging research suggests GLP-1 medications, primarily known for weight loss, may offer an unexpected therapeutic benefit in treating substance addictions.
Smart probiotics capable of sensing high blood sugar and releasing GLP-1 on demand are driving widespread health coverage.
3 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
1 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
2 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
7 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Recent reporting examines the expanding medical landscape surrounding GLP-1 weight loss medications.
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
7 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
7 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
New scientific discoveries regarding brain circuits may redefine the understood mechanism of GLP-1 weight loss drugs like Ozempic and Wegovy.
Researchers are investigating unexpected health benefits of GLP-1 medications as the drugs evolve beyond their primary use for weight loss.
The Department of Veterans Affairs is launching a study to determine if GLP-1 medications can be used to treat alcohol use disorder in veterans.
8 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
2 news sources are covering this Entertainment story right now — PULSE is tracking how fast it spreads.
3 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
3 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
4 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
3 news sources are covering this Entertainment story right now — PULSE is tracking how fast it spreads.
10 news sources are covering this Entertainment story right now — PULSE is tracking how fast it spreads.
9 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
The UK medicines regulator has approved a new once-daily weight-loss pill from Eli Lilly, offering an oral alternative to injectable GLP-1 treatments.
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Kendra Wilkinson returns to the gym for the first time in two years amid her ongoing GLP-1 weight loss journey.
Bank of America is spending $250 million annually on weight loss drugs for staff, highlighting corporate healthcare trends.
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
3 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.